BCL2 and B-cell chronic lymphocytic leukemia: However, the outlook for patients with CLL has improved dramatically with therapies that directly target components of the BCR signaling pathway,5 particularly Bruton tyrosine kinase (Btk), or apoptosis through targeting the Bcl-2 protein.